A way of using nanoparticles to investigate the mechanisms underlying 'mystery' cases of infertility has been developed by scientists at Oxford University.
The technique, published in Nanomedicine: Nanotechnology, Biology and Medicine, could eventually help researchers to discover the causes behind cases of unexplained infertility and develop treatments for affected couples. The method involves loading porous silica nanoparticle 'envelopes' with compounds to identify, diagnose or treat the causes of infertility.
The researchers demonstrated that the nanoparticles could be attached to boar sperm with no detrimental effects on their function.
'An attractive feature of nanoparticles is that they are like an empty envelope that can be loaded with a variety of compounds and inserted into cells,' says Dr Natalia Barkalina, lead author of the study from the Nuffield Department of Obstetrics and Gynaecology at Oxford University. 'The nanoparticles we use don't appear to interfere with the sperm, making them a perfect delivery vessel.
'We will start with compounds to investigate the biology of infertility, and within a few years may be able to explain or even diagnose rare cases in patients. In future we could even deliver treatments in a similar way.'
Sperm are difficult to study due to their small size, unusual shape and short lifetime outside of the body. Yet this is a vital part of infertility research, as senior author Dr Kevin Coward explains: 'To discover the causes of infertility, we need to investigate sperm to see where the problems start. Previous methods involved complicated procedures in animals and introduced months of delays before the sperm could be used.
'Now, we can simply expose sperm to nanoparticles in a petri dish. It's so simple that it can all be done quickly enough for the sperm to survive perfectly unharmed.'
The team, based at the Institute of Reproductive Sciences, used boar sperm because of its similarities to human sperm, as study co-author Celine Jones explains: 'It is similar in size, shape and activity. Now that we have proven the system in boar sperm, we hope to replicate our findings in human sperm and eventually see if we can use them to deliver compounds to eggs as well.'
The research was an interdisciplinary effort, involving reproductive biologists from the Nuffield Department of Obstetrics & Gynaecology and nanoscientists from the Department of Engineering Science led by Dr Helen Townley.
The study was funded by the Nuffield Department of Obstetrics & Gynaecology at Oxford University and the Engineering and Physical Sciences Research Council (EPSRC). This technique is the subject of patent applications held by Isis Innovation, Oxford University's technology transfer arm.
Notes to editors
A report of the research, entitled 'Effects Of Mesoporous Silica Nanoparticles Upon The Function Of Mammalian Sperm In Vitro', is published in this month's Nanomedicine: Nanotechnology, Biology, and Medicine.
The US provisional patent application number for the technique is 61/747781
Oxford University's Medical Sciences Division is one of the largest biomedical research centres in Europe, with over 2,500 people involved in research and more than 2,800 students. The University is rated the best in the world for medicine, and it is home to the UK's top-ranked medical school.
From the genetic and molecular basis of disease to the latest advances in neuroscience, Oxford is at the forefront of medical research. It has one of the largest clinical trial portfolios in the UK and great expertise in taking discoveries from the lab into the clinic. Partnerships with the local NHS Trusts enable patients to benefit from close links between medical research and healthcare delivery.
A great strength of Oxford medicine is its long-standing network of clinical research units in Asia and Africa, enabling world-leading research on the most pressing global health challenges such as malaria, TB, HIV/AIDS and flu. Oxford is also renowned for its large-scale studies which examine the role of factors such as smoking, alcohol and diet on cancer, heart disease and other conditions.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.